CN103908427B - 一种聚乙二醇修饰的rhG-CSF注射液及其制备方法 - Google Patents
一种聚乙二醇修饰的rhG-CSF注射液及其制备方法 Download PDFInfo
- Publication number
- CN103908427B CN103908427B CN201310022113.7A CN201310022113A CN103908427B CN 103908427 B CN103908427 B CN 103908427B CN 201310022113 A CN201310022113 A CN 201310022113A CN 103908427 B CN103908427 B CN 103908427B
- Authority
- CN
- China
- Prior art keywords
- injection
- csf
- rhg
- mpeg
- milliliter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002347 injection Methods 0.000 title claims abstract description 85
- 239000007924 injection Substances 0.000 title claims abstract description 85
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 239000002202 Polyethylene glycol Substances 0.000 title claims abstract description 23
- 229920001223 polyethylene glycol Polymers 0.000 title claims abstract description 23
- 239000003381 stabilizer Substances 0.000 claims abstract description 23
- 239000007951 isotonicity adjuster Substances 0.000 claims abstract description 19
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 14
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 14
- 239000000872 buffer Substances 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000004033 plastic Substances 0.000 claims abstract description 6
- 229920003023 plastic Polymers 0.000 claims abstract description 6
- 229920001427 mPEG Polymers 0.000 claims description 42
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 13
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 12
- 239000000600 sorbitol Substances 0.000 claims description 12
- 238000011068 loading method Methods 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 239000008215 water for injection Substances 0.000 claims description 7
- 229960000583 acetic acid Drugs 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 5
- 239000012362 glacial acetic acid Substances 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 239000001632 sodium acetate Substances 0.000 claims description 5
- 235000017281 sodium acetate Nutrition 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 239000008351 acetate buffer Substances 0.000 claims description 2
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical group CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 7
- 238000003860 storage Methods 0.000 abstract description 3
- 239000011521 glass Substances 0.000 abstract description 2
- 108010044644 pegfilgrastim Proteins 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 229940071846 neulasta Drugs 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 238000004255 ion exchange chromatography Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 230000006920 protein precipitation Effects 0.000 description 3
- 201000010000 Agranulocytosis Diseases 0.000 description 2
- 206010018687 Granulocytopenia Diseases 0.000 description 2
- 229920002651 Polysorbate 85 Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003448 neutrophilic effect Effects 0.000 description 2
- 108010006260 pegylated granulocyte colony-stimulating factor Proteins 0.000 description 2
- 229940113171 polysorbate 85 Drugs 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920005556 chlorobutyl Polymers 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
- 229960001373 pegfilgrastim Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
组分 | 每升用量 | 实际用量 |
醋酸钠 | 1.36g | 1.36×Yg |
吐温80 | 40mg | 40×Yg |
冰醋酸 | 适量 | 调pH3.5~4.5 |
山梨醇 | - | 5%×(批灌装支数M×规格装量)g |
注射用水 | 最后补足体积至Y升 |
组分 | 每升用量 | 实际用量 |
醋酸钠 | 1.36g | 1.36×Yg |
吐温20 | 33mg | 33×Yg |
冰醋酸 | 适量 | 调pH4.0 |
山梨醇 | - | 5%×(批灌装支数M×规格装量)g |
注射用水 | 最后补足体积至Y升 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310022113.7A CN103908427B (zh) | 2013-01-05 | 2013-01-05 | 一种聚乙二醇修饰的rhG-CSF注射液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310022113.7A CN103908427B (zh) | 2013-01-05 | 2013-01-05 | 一种聚乙二醇修饰的rhG-CSF注射液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103908427A CN103908427A (zh) | 2014-07-09 |
CN103908427B true CN103908427B (zh) | 2014-12-17 |
Family
ID=51034634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310022113.7A Active CN103908427B (zh) | 2013-01-05 | 2013-01-05 | 一种聚乙二醇修饰的rhG-CSF注射液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103908427B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112121009B (zh) * | 2020-09-24 | 2022-12-02 | 科兴生物制药股份有限公司 | 一种聚乙二醇修饰重组人粒细胞刺激因子新制剂 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011113601A1 (en) * | 2010-03-17 | 2011-09-22 | Biogenerix Ag | Method for obtaining biologically active recombinant human g-csf |
WO2012021088A1 (en) * | 2010-08-13 | 2012-02-16 | Closed Joint Stock Company "Biocad" | A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycol |
-
2013
- 2013-01-05 CN CN201310022113.7A patent/CN103908427B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011113601A1 (en) * | 2010-03-17 | 2011-09-22 | Biogenerix Ag | Method for obtaining biologically active recombinant human g-csf |
WO2012021088A1 (en) * | 2010-08-13 | 2012-02-16 | Closed Joint Stock Company "Biocad" | A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycol |
Non-Patent Citations (3)
Title |
---|
Annemiek B. van Spriel,等人.A SINGLE INJECTION OF POLYETHYLENE-GLYCOL GRANULOCYTE COLONY-STIMULATING FACTOR STRONGLY PROLONGS SURVIVAL OF MICE WITH SYSTEMIC CANDIDIASIS..《CYTOKINE》.2000,第12卷(第6期), * |
新浪资讯.津优力药品说明书.《新浪网新闻资讯》.2012, * |
新药研发.石药集团两个抗肿瘤新药上市.《中国处方药》.2012,第10卷(第1期), * |
Also Published As
Publication number | Publication date |
---|---|
CN103908427A (zh) | 2014-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100475267C (zh) | 含甘氨酸的高浓度人生长激素液体制剂 | |
KR101454646B1 (ko) | 히알루로니다아제의 안정화 제제 및 이를 포함하는 액상제제 | |
CN102988984A (zh) | 增强稳定性的抗TNF-α人单克隆抗体的含水药物制剂 | |
CN103463565B (zh) | 一种莪术油注射液及其制备方法 | |
CN1840177B (zh) | 胸腺肽α1注射液及其制备方法 | |
CN103908427B (zh) | 一种聚乙二醇修饰的rhG-CSF注射液及其制备方法 | |
CN102813632A (zh) | 一种稳定的胸腺法新制剂及其制备方法 | |
CN101953781B (zh) | 盐酸伊立替康溶液型注射剂及其制备方法 | |
CN102151257B (zh) | 一种白消安注射剂及其制备方法 | |
CN102784382A (zh) | 一种阿加曲班药物组合物及其制备方法和应用 | |
CN106729627B (zh) | 一种重组人促红细胞生成素制剂 | |
CN101336903B (zh) | 注射用左旋奥硝唑磷酸二钠静脉制剂的制备方法 | |
CN105597079A (zh) | 用于治疗银屑病的药物 | |
CN107865824B (zh) | 一种稳定的重组人血管内皮抑制素皮下注射组合物 | |
CN104606209A (zh) | 一种注射用复方维生素药物组合物及其制备方法 | |
CN112156067B (zh) | 一种含有米力农的药物组合物及其制备方法 | |
CN104069061A (zh) | 一种含普乐沙福的注射用组合物及其制备方法和应用 | |
CN104490902B (zh) | 一种注射用复方维生素冻干粉针剂组合物及其制备方法 | |
CN1371284A (zh) | 多剂量红细胞生成素制剂 | |
CN103432086B (zh) | 一种注射用培美曲塞二钠冻干粉针剂及其制备方法 | |
CN101843896A (zh) | 高浓度低装量重组人干扰素α2b注射液 | |
CN102327239A (zh) | 鲑鱼降钙素纳米脂质体注射剂及制备方法 | |
CN105796487B (zh) | 一种米力农注射液及其制备方法 | |
CN100502944C (zh) | 一种天门冬酰胺酶注射液、其制备方法及应用 | |
CN104244925B (zh) | 盐酸氢吗啡酮溶液的提高的稳定性 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Liu Jia Document name: Notification of Passing Examination on Formalities |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 212 Jinbu street, Qinshui Korea Industrial Park, Muping District, Yantai City, Shandong Province 264100 Patentee after: Baike (Shandong) biopharmaceutical Co., Ltd. of Shiyao Group Country or region after: China Address before: 212 Jinbu street, Qinshui Korea Industrial Park, Muping District, Yantai City, Shandong Province 264100 Patentee before: CSPC BAIKE (SHANDONG) BIOPHARMACEUTICAL CO.,LTD. Country or region before: China |